CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is being studied in laboratory and clinical research involving metabolic signaling, appetite regulation, glucose control, and body-weight pathways. OasBioScience provides CagriSema research material with analytical quality information to support identification and characterization.
Select options
This product has multiple variants. The options may be chosen on the product page
Premium Research Peptides OasBioScience provides high-purity research peptides, laboratory-tested compounds, and reliable worldwide service for professional research and educational purposes.